Search clinical trials for: Essential thrombocythemia

Total 1550 results

National Institutes of Health Clinical Center (CC)

Completed

Molecular Changes and Biomarkers in Chronic Myeloproliferative Disorders

Polycythemia Vera | Chronic Myeloproliferative Disorders | Essential Thrombocytosis | Idiopathic Myelofibrosis | Neutrophils

United States
Onconova Therapeutics, Inc.

Completed

Safety and Efficacy of 72-hour and 120-hour Infusion of Rigosertib in Acute Myeloid Leukemia (AML) and Acute Lymphoid Leukemia (ALL)

Chronic Myeloid Leukemia | Acute Lymphocytic Leukemia | Acute Myelocytic Leukemia | Myeloproliferative Disease

United States
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Terminated

Donor Umbilical Cord Blood Transplant in Treating Patients With Advanced Hematological Cancer or Other Disease

Lymphoma | Myelodysplastic Syndromes | Leukemia | Multiple Myeloma and Plasma Cell Neoplasm | Myelodysplastic/Myeloproliferative Diseases

United States
Wake Forest University Health Sciences
National Cancer Institute (NCI)

Completed

Music in Reducing Anxiety and Pain in Adult Patients Undergoing Bone Marrow Biopsy for Hematologic Cancers or Other Diseases

Pain | Lymphoma | Myelodysplastic Syndromes | Leukemia | Chronic Myeloproliferative Disorders | Multiple Myeloma and Plasma Cell Neoplasm | Precancerous Condition | Psychosocial Effects of Cancer and Its Treatment | Lymphoproliferative Disorder | Myelodysplastic/Myeloproliferative Neoplasms

United States
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Completed

Fludarabine and Total-Body Irradiation Followed By Donor Stem Cell Transplant and Cyclosporine and Mycophenolate Mofetil in Treating HIV-Positive Patients With or Without Cancer

HIV Infection | Unspecified Childhood Solid Tumor, Protocol Specific | Primary Myelofibrosis | Polycythemia Vera | Essential Thrombocythemia | Stage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Chronic Myelomonocytic Leukemia | Juvenile Myelomonocytic Leukemia | Extranodal... and other conditions

United States
AstraZeneca
University of Texas; Gustave Roussy, Cancer Campus, Grand Paris; New York City...

Completed

Study to Assess the Safety of AZD1480 in Patients With Myeloproliferative Diseases

Primary Myelofibrosis (PMF) | Post-Polycythaemia Vera | Essential Thrombocythaemia Myelofibrosis

United States, France
Vanderbilt University
National Cancer Institute (NCI)

Completed

Methemoglobinemia in Young Patients With Hematologic Cancer or Aplastic Anemia Treated With Dapsone

Lymphoma | Myelodysplastic Syndromes | Leukemia | Chronic Myeloproliferative Disorders | Multiple Myeloma and Plasma Cell Neoplasm | Nonmalignant Neoplasm | Lymphoproliferative Disorder | Myelodysplastic/Myeloproliferative Neoplasms | Methemoglobinemia

United States
Eli Lilly and Company

Completed

Study of LY2784544 Testing Alternative Dosing in Participants With Myeloproliferative Neoplasms

Polycythemia Vera | Essential Thrombocythemia | Myelofibrosis | Myeloproliferative Neoplasms of

United States
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Completed

Biological Therapy in Treating Patients With Advanced Myelodysplastic Syndrome, Acute or Chronic Myeloid Leukemia, or Acute Lymphoblastic Leukemia Who Are Undergoing Stem Cell Transplantation

Polycythemia Vera | Essential Thrombocythemia | Chronic Myelomonocytic Leukemia | Recurrent Adult Acute Myeloid Leukemia | Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities | Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) | Adult Acute Myeloid Leukemia With t(16;16)(p13;q22) | Adult... and other conditions

United States
Galena Biopharma, Inc.

Completed

A Study of Anagrelide Controlled Release (GALE-401) in Patients With High Platelet Counts Due to Bone Marrow Disorders

Thrombocytosis | Myeloproliferative Neoplasms

United States
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI)

Completed

American Ginseng in Treating Patients With Fatigue Caused by Cancer

Lymphoma | Myelodysplastic Syndromes | Leukemia | Fatigue | Chronic Myeloproliferative Disorders | Unspecified Adult Solid Tumor, Protocol Specific | Multiple Myeloma and Plasma Cell Neoplasm | Precancerous Condition | Lymphoproliferative Disorder | Myelodysplastic/Myeloproliferative Neoplasms

United States
University of Cambridge
Cambridge University Hospitals NHS Foundation Trust; Institute of Cancer Research...

Completed

Primary Thrombocythaemia 1 Trial (PT-1)

Myeloproliferative Disorder | Thrombocythemia

United Kingdom
Ronald Hoffman
National Cancer Institute (NCI); Roche Pharma AG; Myeloproliferative Disorders-Research...

Completed

Pegylated Interferon Alfa-2a Salvage Therapy in High Risk Polycythemia Vera (PV) or Essential Thrombocythemia (ET)

High Risk Polycythemia Vera | High Risk Essential Thrombocythemia

United States, Italy
Yale University
National Cancer Institute (NCI)

Completed

Alemtuzumab and Combination Chemotherapy Followed By Donor Lymphocytes in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer

Lymphoma | Myelodysplastic Syndromes | Leukemia | Chronic Myeloproliferative Disorders | Myelodysplastic/Myeloproliferative Neoplasms

United States
Hospital Israelita Albert Einstein

Completed

Study of Molecular and Genetic Abnormalities in Patients With Myeloid Neoplasms

Acute Myeloid Leukemia | Myelodysplastic Syndromes | Myeloproliferative Neoplasms | Myeloproliferative/Myelodysplastic Neoplasm

Brazil
Northwestern University
National Cancer Institute (NCI)

Withdrawn

Siltuximab in Treating Patients With Primary, Post-Polycythemia Vera, or Post-Essential Thrombocythemia Myelofibrosis

Primary Myelofibrosis | Polycythemia Vera | Myelofibrosis | Thrombocytopenia
Mitsubishi Tanabe Pharma Corporation

Completed

Clinical Management of Argatroban in Patients With Heparin Induced Thrombocytopenia Type II

Heparin-induced Thrombocytopenia Type II

France
Novartis Pharmaceuticals

Completed

A Clinical Study of Ruxolitinib in Patients With Primary Myelofibrosis (PM), Post-polycythemia Vera (PV) Myelofibrosis, or Post-essential Thrombocythemia (ET) Myelofibrosis

Primary Myelofibrosis (MF)

Japan
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI)

Completed

Ondansetron in Treating Patients With Advanced Cancer and Chronic Nausea and Vomiting Not Caused by Cancer Treatment

Lymphoma | Unspecified Childhood Solid Tumor, Protocol Specific | Myelodysplastic Syndromes | Leukemia | Chronic Myeloproliferative Disorders | Small Intestine Cancer | Unspecified Adult Solid Tumor, Protocol Specific | Multiple Myeloma and Plasma Cell Neoplasm | Precancerous Condition | Nausea and Vomiting

United States
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI)

Terminated

506U78 in Treating Patients With Hematologic Cancer and Kidney or Liver Impairment

Lymphoma | Myelodysplastic Syndromes | Leukemia | Chronic Myeloproliferative Disorders | Multiple Myeloma and Plasma Cell Neoplasm

United States
AOP Orphan Pharmaceuticals AG

Completed

Anagrelide Retard vs. Placebo: Efficacy and Safety in "At-risk" Patients With Essential Thrombocythaemia (ARETA)

Essential Thrombocythaemia

Poland, Slovakia, Bulgaria, Russian Federation, Romania, Croatia, Lithuania, Austria, Ukraine
Memorial Sloan Kettering Cancer Center
Novartis

Terminated

HSP90 Inhibitor, AUY922, in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (Post-PV MF), Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF), and Refractory PV/ET

Myeloproliferative Neoplasms

United States
Shandong University

Withdrawn

Cell Cycle Regulatory Gene Study in Patients With Myeloproliferative Disorders

Myeloproliferative Disorders | Polycythemia Vera | Essential Thrombocythemia | Myelofibrosis | Chronic Myeloid Leukemia

China
Sanofi

Completed

Study With SAR302503 in Patients With Polycythemia Vera or Essential Thrombocythemia

Hematopoietic Neoplasm

United States, Spain, France, Canada, Australia, Korea, Republic of, Germany, Italy, United Kingdom
Geron Corporation

Completed

Open Label Study to Evaluate the Activity of Imetelstat in Patients With Essential Thrombocythemia or Polycythemia Vera (ET/PV)

Polycythemia Vera | Essential Thrombocythemia

United States, Germany, Switzerland
Mayo Clinic
National Cancer Institute (NCI)

Terminated

Low-Dose Decitabine in Treating Patients With Symptomatic Myelofibrosis

Chronic Myeloproliferative Disorders | Secondary Myelofibrosis

United States
Cephalon

Completed

Open-Label Study of Oral CEP-701 (Lestaurtinib) in Patients With Polycythemia Vera or Essential Thrombocytosis

Polycythemia Vera | Essential Thrombocytosis

United States
Sidney Kimmel Comprehensive Cancer Center at Johns...
National Cancer Institute (NCI)

Completed

Fludarabine, Cyclophosphamide, and Total-Body Irradiation in Treating Patients Who Are Undergoing a Donor Bone Marrow Transplant for Hematologic Cancer

Lymphoma | Myelodysplastic Syndromes | Leukemia | Chronic Myeloproliferative Disorders | Multiple Myeloma and Plasma Cell Neoplasm

United States
AOP Orphan Pharmaceuticals AG

Completed

Anagrelide Retard in Essential Thrombocythemia (TEAM-ET)

Essential Thrombocythemia

Austria, Bulgaria, Lithuania, Poland, Russian Federation
City of Hope Medical Center
National Cancer Institute (NCI)

Terminated

Influenza Vaccine in Preventing Flu in Patients Who Have Undergone Stem Cell Transplant and in Healthy Volunteers

Lymphoma | Myelodysplastic Syndromes | Leukemia | Chronic Myeloproliferative Disorders | Brain and Central Nervous System Tumors | Multiple Myeloma and Plasma Cell Neoplasm | Nonmalignant Neoplasm | Lymphoproliferative Disorder | Myelodysplastic/Myeloproliferative Neoplasms | Viral Infection

United States
Ronald Hoffman
Novartis

Unknown

LBH589 (Panobinostat) for the Treatment of Myelofibrosis

Primary Myelofibrosis | Polycythemia Vera, Post-Polycythemic Myelofibrosis Phase | Post-Essential Thrombocythemia Related Myelofibrosis

United States
Novartis Pharmaceuticals

Completed

Exploratory Phase II Study of INC424 Patients With Primary Myelofibrosis (PMF) or Post Polycythaemia Myelofibrosis (PPV MF) or Post Essential Thrombocythaemia Myelofibrosis (PET-MF) (MACS2030)

Primary Myelofibrosis (PMF) | Post Polycythaemia Myelofibrosis (PPV MF) | Post Essential Thrombocythaemia Myelofibrosis (PET-MF)

United Kingdom
National Cancer Institute (NCI)

Completed

3-AP and Fludarabine in Treating Patients With Myeloproliferative Disorders, Chronic Myelomonocytic Leukemia, or Accelerated Phase or Blastic Phase Chronic Myelogenous Leukemia

Primary Myelofibrosis | Polycythemia Vera | Essential Thrombocythemia | Chronic Myelomonocytic Leukemia | Accelerated Phase Chronic Myelogenous Leukemia | Relapsing Chronic Myelogenous Leukemia | Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative | Philadelphia Chromosome Negative Chronic Myelogenous... and other conditions

United States
John Mascarenhas

Terminated

Anti-TGF-beta Therapy in Patients With Myelofibrosis

Primary Myelofibrosis | Myelofibrosis | Polycythemia Vera, Post-Polycythemic Myelofibrosis Phase | Post-essential Thrombocythemia Related Myelofibrosis

United States
Ronald Hoffman
National Cancer Institute (NCI); Myeloproliferative Disorders-Research Consortium

Unknown

CEP-701 (Lestaurtinib) in Myelofibrosis

Polycythemia Vera | Essential Thrombocythemia | Myelofibrosis

United States
Children's Oncology Group
National Cancer Institute (NCI)

Completed

INCB18424 in Treating Young Patients With Relapsed or Refractory Solid Tumor, Leukemia, or Myeloproliferative Disease

Unspecified Childhood Solid Tumor, Protocol Specific | Myelodysplastic Syndromes | Leukemia | Chronic Myeloproliferative Disorders | Myelodysplastic/Myeloproliferative Neoplasms

United States
Sanofi

Completed

Phase 2 Study in Japanese Patients With Intermediate-2 or High Risk Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, Post-Essential Thrombocythemia Myelofibrosis With Splenomegaly

Myelofibrosis

Japan
Indiana University School of Medicine
National Cancer Institute (NCI)

Completed

EMD 121974 in Treating Patients With Locally Advanced or Metastatic Cancer

Lymphoma | Myelodysplastic Syndromes | Leukemia | Chronic Myeloproliferative Disorders | Small Intestine Cancer | Unspecified Adult Solid Tumor, Protocol Specific | Multiple Myeloma and Plasma Cell Neoplasm | Precancerous/Nonmalignant Condition

United States
National Cancer Institute (NCI)

Completed

Lenalidomide and Prednisone in Treating Patients With Myelofibrosis

Primary Myelofibrosis | Polycythemia Vera | Essential Thrombocythemia

United States
National Cancer Institute (NCI)

Completed

Sunitinib Malate in Treating HIV-Positive Patients With Cancer Receiving Antiretroviral Therapy

HIV Infection | Clear Cell Renal Cell Carcinoma | Primary Myelofibrosis | Polycythemia Vera | Essential Thrombocythemia | Chronic Myelomonocytic Leukemia | Recurrent Adult Acute Myeloid Leukemia | Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue | Nodal Marginal Zone B-cell... and other conditions

United States
INSYS Therapeutics Inc
National Cancer Institute (NCI)

Completed

Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain

Cancer

United States
National Cancer Institute (NCI)

Completed

Imatinib Mesylate in Treating Patients With Myelofibrosis

Primary Myelofibrosis | Polycythemia Vera | Essential Thrombocythemia | Chronic Myelomonocytic Leukemia

United States
M.D. Anderson Cancer Center
S*BIO

Completed

Study of SB939 in Subjects With Myelofibrosis

Myeloproliferative Disorders

United States
University of California, San Francisco
National Cancer Institute (NCI)

Unknown

Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer, Metastatic Kidney Cancer, or Aplastic Anemia

Lymphoma | Kidney Cancer | Myelodysplastic Syndromes | Leukemia | Chronic Myeloproliferative Disorders | Multiple Myeloma and Plasma Cell Neoplasm | Myelodysplastic/Myeloproliferative Neoplasms

United States
The Cleveland Clinic

Unknown

Combination Chemotherapy Plus Amifostine in Treating Patients With Advanced Cancer

Lymphoma | Myelodysplastic Syndromes | Leukemia | Chronic Myeloproliferative Disorders | Unspecified Adult Solid Tumor, Protocol Specific | Multiple Myeloma and Plasma Cell Neoplasm | Precancerous Condition | Drug/Agent Toxicity by Tissue/Organ

United States
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)

Completed

Pyroxamide in Treating Patients With Advanced Cancer

Lymphoma | Myelodysplastic Syndromes | Leukemia | Chronic Myeloproliferative Disorders | Small Intestine Cancer | Unspecified Adult Solid Tumor, Protocol Specific | Multiple Myeloma and Plasma Cell Neoplasm | Precancerous Condition

United States
National Cancer Institute (NCI)

Completed

Tipifarnib in Treating Patients With Myelofibrosis and Myeloid Metaplasia

Primary Myelofibrosis | Polycythemia Vera | Essential Thrombocythemia

United States
BioCryst Pharmaceuticals

Completed

BCX-1777 in Treating Patients With Refractory Cancer

Cancer

United States
National Cancer Institute (NCI)

Completed

Vorinostat, Cytarabine, and Etoposide in Treating Patients With Relapsed and/or Refractory Acute Leukemia or Myelodysplastic Syndromes or Myeloproliferative Disorders

Primary Myelofibrosis | Polycythemia Vera | Essential Thrombocythemia | Chronic Myelomonocytic Leukemia | Recurrent Adult Acute Myeloid Leukemia | Adult Acute Megakaryoblastic Leukemia (M7) | Adult Acute Minimally Differentiated Myeloid Leukemia (M0) | Adult Acute Monoblastic Leukemia (M5a) | Adult... and other conditions

United States
National Heart, Lung, and Blood Institute (NHLBI)

Terminated

Peripheral Stem Cell Transplant in Treating Patients With High-Risk Leukemia

Leukemia | Chronic Myeloproliferative Disorders | Myelodysplastic/Myeloproliferative Diseases

United States

Search clinical trials for: Essential thrombocythemia

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Luxembourg

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations